Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry

Piver, M. Steven; Jishi, Mohannad F.; Tsukada, Yoshiaki; Nava, Guillermina

doi:10.1002/1097-0142(19930501)71:9<2751::aid-cncr2820710911>3.0.co;2-j

Cited by 308 publications

(99 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, at the time of the diagnosis of PPSC no malignant lesions were found in the fallopian tubes. Furthermore, it has been shown that PPSC has developed after salpingo-oophorectomy (Piver et al, 1993). So, we have concluded that PPSC is a primary tumour and not a metastasis.…”

Section: Discussionmentioning

confidence: 61%

“…Second, the later study also includes 42 BRCA2 carriers (43%), while the incidence in our series is established for BRCA1 carriers who have a higher intrinsic ovarian cancer risk, and this may also be true for PPSC. Other studies neither described procedures nor whether the cases were BRCA1 or BRCA2 mutation carriers (Piver et al, 1993;Rebbeck et al, 2002). Our series of 64 BRCA1 and BRCA2 mutation carriers after salpingo-oophorectomy includes only six BRCA2 carriers (9.4%).…”

Section: Discussionmentioning

confidence: 97%

“…Given the anatomy, a hysterectomy cannot prevent the development of PPSC. Piver et al (1993) described nine cases of PPSC after abdominal total hysterectomy and salpingo-oophorectomy.…”

Section: Discussionmentioning

confidence: 99%

“…The development of peritoneal papillary serous carcinoma (PPSC) has also been observed after prophylactic surgery of the ovaries. (Tobacman et al, 1982;Chen et al, 1985;Lynch et al, 1986Lynch et al, , 1991Piver et al, 1993;Kauff et al, 2002;Rebbeck et al, 2002). No comparison has been made between the outcome of a bilateral oophorectomy and the outcome of a bilateral salpingo-oophorectomy.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

et al. 2004

View full text Add to dashboard Cite

A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation carriers and members of a hereditary breast/ovarian cancer (HBOC) family, who had undergone prophylactic surgery, were reviewed. In all, 38 women underwent a bilateral oophorectomy (26 BRCA1, three BRCA2 and nine HBOC, respectively). A total of 90 women underwent bilateral salpingooophorectomy (58 BRCA1, six BRCA2, one BRCA1 and 2, 25 HBOC, respectively). At the time of salpingo-oophorectomy, five of 58 BRCA1 carriers (8.6%) were diagnosed with an occult carcinoma: two fallopian tube carcinomas, two ovarian carcinomas and one case was defined as a fallopian tube/ovarian carcinoma. No occult carcinomas were found in the other groups. Of the 38 patients, who underwent a bilateral oophorectomy (mean follow-up 45 months), three of 26 BRCA1 mutation carriers (3.4 in 100 womenyears) developed peritoneal papillary serous carcinoma (PPSC) during follow-up. So far, no PPSC have occurred in the 90 women, who underwent a salpingo-oophorectomy (mean follow-up 12 months), including 58 BRCA1 carriers (0 in 60 in women-years). These results contribute to the thesis that BRCA1 germline mutation carriers are not only at risk for ovarian cancer, but also for fallopian tube carcinoma and peritoneal papillary serous carcinoma. Our data suggest that PPSC risk among BRCA2 carriers is lower than among BRCA1 carriers.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 97%

“…Given the anatomy, a hysterectomy cannot prevent the development of PPSC. Piver et al (1993) described nine cases of PPSC after abdominal total hysterectomy and salpingo-oophorectomy.…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This is not unexpected in the light of previous studies reporting a low risk of PPC. 27,31,32 In the recent study by Finch et al 33 in women who had undergone SO, the annual risk of PPC was estimated to be 0.217% in BRCA1 carriers and 0.167% in BRCA2 carriers. On the basis of these estimates, less than 1 case would have been expected in our series.…”

Section: Discussionmentioning

confidence: 85%

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Laki

Kirova

This

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Prophylactic salpingo‐oophorectomy (SO), which is recommended in BRCA1/2 mutation carriers, still needs to be reappraised.METHODS.In all, 89 BRCA1/BRCA2 mutation carriers underwent SO between 1994–2004. Past medical and familial history, SO, results and survival after SO were analyzed.RESULTS.The series consisted of 56 BRCA1 and 33 BRCA2 mutation carriers. All but 1 had a family history of breast (BC) and/or ovarian cancer; 42 BRCA1 and 31 BRCA2 had a personal history of BC. The median age at SO was 44 (BRCA1) and 49.5 (BRCA2) years for women without previous BC (not significant) and 48 (BRCA1) and 53 BRCA2) years (P = .03) for women with previous BC. Occult ovarian (n = 2) and/or fallopian (n = 3) carcinomas were found in 4 patients (4.5%): 1 experienced recurrence (4 years), 2 are disease‐free (26 and 38 months of follow‐up), and 1 died from BC (12 months). Among the other 69 patients with previous BC (median follow‐up, 42 months), 14 developed ipsilateral or contralateral BC and 8 developed metastatic disease. Among the 16 patients without previous BC (median follow‐up, 27 months), 3 developed BC. Of the 89 patients, 85 are still alive: 3 died from BC and 1 died from pancreatic cancer. No peritoneal malignancy was observed.CONCLUSIONS.This study shows that prophylactic SO remains an important option for BRCA1/2 mutation carriers as asymptomatic ovarian/fallopian cancers were found in 4.5% of patients. However, a longer follow‐up and larger series are required to more precisely evaluate the benefits of this procedure in terms of BC incidence, peritoneal malignancy, or recurrence. Cancer 2007. © 2007 American Cancer Society.

show abstract

Familial Ovarian Cancer

1991

JAMA

View full text Add to dashboard Cite

OBJECTIVETo assist family physicians in evaluating patients' risk for hereditary ovarian cancer and to review strategies for preventing ovarian cancer. QUALITY OF EVIDENCEThe MEDLINE, EMBASE, CANCERLIT, and CINAHL databases were searched from 1970 to 1999 using key words related to hereditary ovarian cancer, screening, oral contraceptives, prophylactic oophorectomy, cancer worriers, satisfaction, and perceived risk. Recommendations in this paper are based on evidence from case-control and cohort studies and, where appropriate, consensus conferences.MAIN MESSAGE Of all women who present with ovarian cancer, 20% have a family history of ovarian cancer and 8% carr y a BRCA 1 or BRCA 2 mutation. Women who carr y a BRCA 1 mutation have a 63% lifetime risk of developing ovarian cancer, and women who carry a BRCA 2 mutation have a 27% lifetime risk of developing ovarian cancer. Preventive strategies include screening (level 3 evidence for postmenopausal women and level 5 evidence for women with a family history of ovarian cancer), use of oral contraceptives (level 3 evidence for the general population and for mutation carriers), and prophylactic oophorectomy (level 3 evidence in firstdegree relatives of patients with breast or ovarian cancer).CONCLUSION Women who have a family history of ovarian cancer should be offered genetic counseling and discussion of various preventive strategies for minimizing their risk.OBJECTIF Aider les médecins de famille à évaluer le risque de cancer héréditaire des ovaires chez leurs patientes et examiner les stratégies de prévention du cancer ovarien.QUALITÉ DES DONNÉES Une recension a été effectuée dans les bases de données MEDLINE, EMBASE, CANCERLIT et CINAHL de 1970 à 1999 à l'aide de mots clés associés au cancer héréditaire des ovaires, au dépistage, aux contraceptifs oraux, à l'ovariectomie prophylactique, aux personnes inquiètes du cancer, à la satisfaction et au risque perçu. Les recommandations du présent document se fondent sur les données probantes tirées d'études de castémoins et de cohortes et de conférences consensuelles s'il y a lieu.PRINCIPAL MESSAGE Chez toutes les femmes qui sont atteintes d'un cancer ovarien, 20% ont des antécédents familiaux de ce type de cancer et 8% présentent une mutation au gène BRCA1 ou BRCA2. Les femmes porteuses d'une mutation au gène BRCA1 ont 63% de risque de développer un cancer ovarien durant leur vie et chez celles qui ont une mutation au gène BRCA2, ce risque s'élève à 27%. Au nombre des stratégies de prévention figurent le dépistage (données probantes de niveau 3 pour les femmes après la ménopause et de niveau 5 pour celles qui ont des antécédents familiaux de cancer ovarien), le recours aux contraceptifs oraux (données probantes de niveau 3 pour l'ensemble de la population et les porteuses de mutations génétiques) et une ovariectomie prophylactique (données probantes de niveau 3 pour les patientes ayant des parentes du premier degré ayant souffert d'un cancer du sein ou des ovaires).CONCLUSION Il faudrait offrir un counseling génétique au...

show abstract

Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry

Cited by 308 publications

References 10 publications

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Familial Ovarian Cancer

Contact Info

Product

Resources

About